Pharmaceutical composition for preventing or treating sarcopenia comprising non-natural alanine derivatives

The D-alanine derivative D-Ala-Oi-pr-HCl inhibits myostatin to address muscle atrophy, enhancing muscle mass and strength in animal models, offering a more effective treatment than existing therapies.

KR103045816B1Active Publication Date: 2026-11-10KOREA UNIV RES & BUSINESS FOUND
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
KR1020240055482
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2024-04-25
Publication Date
2026-11-10
Estimated Expiration
2044-04-25

AI Technical Summary

Technical Problem

Current treatments for muscle atrophy, such as exercise, drug therapy, and dietary therapy, are inadequate for long-term muscle mass maintenance, and existing drugs have side effects or inefficacies, while myostatin inhibitors are sought to address muscle loss and reduced strength.

Method used

A D-alanine derivative, (R)-isopropyl 2-aminopropanoate hydrochloride (D-Ala-Oi-pr-HCl), is developed to inhibit myostatin expression and promoter activity, reducing muscle atrophy and enhancing muscle strength.

Benefits of technology

D-Ala-Oi-pr-HCl effectively inhibits myostatin production, leading to increased muscle mass and strength in animal models of atrophy, providing a more fundamental treatment for muscle atrophy conditions like sarcopenia and cachexia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112024045700354-PAT00011_ABST
    Figure 112024045700354-PAT00011_ABST
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition for the prevention or treatment of muscle atrophy containing a non-natural alanine derivative as an active ingredient. Since the non-natural alanine derivative of the present invention inhibits the increase in the production and mRNA expression of myostatin protein, which directly affects muscle loss and muscle strength reduction, it is expected to be used in various fields such as pharmaceuticals, non-pharmaceuticals, cosmetic materials, functional biomaterials, and functional food materials for the improvement, prevention, or treatment of fundamental muscle atrophy.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to a pharmaceutical composition for the prevention or treatment of muscle atrophy containing a D-alanine derivative as an active ingredient. Background Technology

[0003] Decreased muscle mass can occur naturally as the body ages, or it may be caused by muscle disuse or lack of exercise, or it may occur secondarily due to other pathological conditions (cachexia, sepsis, starvation, chemotherapy, excessive exposure to stress hormones). This can be collectively attributed to muscle cell atrophy resulting from the antianabolic and catabolic actions of Type I and II muscle fibers.

[0004] In many cases, the body's stress hormones (Cortisol, Glucocorticoids, inner GCs) induce molecular biological changes in muscle fibers, thereby directly or indirectly participating in anabolic and catabolic processes. GCs act as an anti-anabolic agent by inhibiting the PI3K / Akt / mTOR pathway; this inhibits the activity of downstream effectors such as 4E-BP1 and S6K1, thereby blocking the function of eIF4G (Eukaryotic translation initiation factor 4G) and eIF4E (Eukaryotic translation initiation factor 4E). This inhibits the mRNA translation process necessary for protein synthesis, resulting in inhibition of muscle fiber synthesis and muscle atrophy due to protein degradation. GCs play a role in inducing muscle atrophy not only by inhibiting muscle synthesis but also by degrading proteins. This leads to the expression of atrogenes (Atrogin-1 / MAFbx, MuRF-1) that induce atrophy according to the mechanism resulting from 'PI3K / Akt -> FOXO activation and GSK3 inactivation,' and these genes induce protein degradation represented by the ubiquitin-proteasome system.

[0005] The concept of sarcopenia began in 1989 when Irwin Rosenberg introduced the term 'sarcopenia.' Its origins in Greek, where it is a compound word formed from "sarco," meaning muscle, and "penia," meaning reduced. Sarcopenia refers to a decline in muscle strength resulting from a decrease in muscle mass associated with aging. Here, "muscle" refers to skeletal muscle and is unrelated to smooth muscle. In other words, sarcopenia signifies a loss of skeletal muscle mass, primarily distributed in the limbs, and is distinguished from cachexia—a state of significant muscle loss occurring in the terminal stages of malignant tumors—muscle wasting caused by acute diseases such as influenza, or primary muscle disease.

[0006] There are three main treatment methods for sarcopenia. The first is exercise. Exercise is reported to increase the protein synthesis capacity of skeletal muscle in the short term and improve muscle strength and mobility in the elderly. However, it is unsuitable as a long-term treatment method. The second is drug therapy; while the use of testosterone or anabolic steroids is possible, they induce masculinization in women and cause side effects such as prostate symptoms in men. Other approved treatments include DHEA (dehydroepiandrosterone) and growth hormone, and studies have reported that SARMs (Selective Androgen Receptor Modulators) can be effective treatments. Additionally, although dietary therapy is known as a treatment, nutritional assessments indicate that malnutrition or modern dietary habits are inadequate for maintaining an appropriate total body mass.

[0007] Myostatin is a polypeptide growth factor belonging to the TGF-β superfamily. TGF-β possesses a large number of isoforms and is known to be involved in cell proliferation, apoptosis, differentiation, and the formation and maintenance of bone (Massague & Chen, 2000). Myostatin belongs to Growth Differentiation Factor (GDF) 8 and acts by activating the Smad signaling pathway, participating in tissue growth and development. Additionally, it has been reported to influence bone formation and regeneration by inhibiting the cell cycle and the proliferation of progenitor cells via the p21 gene. Myostatin is primarily produced in skeletal muscle cells and causes muscle loss and muscle strength reduction through autocrine mechanisms; it is also known to inhibit protein synthesis and cell proliferation in myoblasts by suppressing the expression of IGF-1 or Follistatin, which are involved in muscle hypertrophy. Prior art literature

[0009] KR 10-2019-0117223 The problem to be solved

[0010] Against this backdrop, the inventors made diligent efforts to discover a substance capable of treating muscle atrophy by inhibiting myostatin expression and promoter activity, which cause muscle loss and reduced muscle strength. As a result, they synthesized (R)-isopropyl 2-aminopropanoate hydrochloride (D-Ala-Oi-pr-HCl), a D-alanine derivative, and confirmed the down-regulating function of the D-alanine derivative on myostatin, thereby completing the present invention.

[0011] The object of the present invention is to provide the above-mentioned D-alanine derivative and its use for improving, preventing, and / or treating muscle atrophy.

[0012] However, the technical problems that the present invention aims to solve are not limited to those mentioned above, and other unmentioned problems will be clearly understood by a person skilled in the art from the description below. means of solving the problem

[0014] To solve the above problem, the present invention provides D-alanine isopropyl ester hydrochloride ((R)-isopropyl 2-aminopropanoate hydrochloride, D-Ala-Oi-pr-HCl), which is a non-natural alanine derivative having the structure of Chemical Formula 1 below.

[0015] [Chemical Formula 1]

[0016]

[0017] In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of muscle atrophy comprising the above-mentioned non-natural alanine derivative as an active ingredient.

[0018] In addition, the present invention provides a food composition for improving or preventing muscle atrophy comprising the above-mentioned non-natural alanine derivative as an active ingredient.

[0019] In another embodiment of the present invention, the non-natural alanine derivative may reduce myostatin promoter activity.

[0020] As another embodiment of the present invention, the composition may contain the non-natural alanine derivative at a concentration of 0.001 mM to 10 mM.

[0021] In another embodiment of the present invention, the muscle atrophy may be one or more muscle atrophies selected from the group consisting of sarcopenia, disuse atrophy, muscle atrophy due to absence of mechanical stimulation, denervational atrophy, cachexia, drug-induced atrophy, malnutritional atrophy, and muscular dystrophy.

[0022] In addition, the present invention provides a formulation for the prevention or treatment of muscle atrophy, characterized by comprising one or more selected from the group consisting of pharmaceutically acceptable carriers, excipients, diluents, stabilizers, and preservatives, and the pharmaceutical composition described above.

[0023] In one embodiment of the present invention, the pharmaceutically acceptable carrier may comprise a carrier for oral administration or a carrier for parenteral administration.

[0024] In addition, the present invention provides a method for preventing or treating muscle atrophy comprising the step of administering the above-mentioned non-natural alanine derivative to an individual, and the method may further include the step of measuring the individual's muscle strength before and after administration.

[0025] In addition, the present invention provides a use for the manufacture of a drug for preventing or treating muscle atrophy using the above-mentioned non-natural alanine derivative. Effects of the invention

[0027] A pharmaceutical composition for the prevention or treatment of muscle atrophy containing a D-alanine derivative of the present invention as an active ingredient inhibits the increase in the production and mRNA expression of myostatin protein, which directly affects muscle loss and muscle strength reduction, and thus can exhibit a more fundamental effect of improving, preventing, or treating muscle atrophy. Brief explanation of the drawing

[0029] Figure 1 shows the molecular structures of D-alanine and D-Ala-Oi-pr-HCl. Figure 2 shows the results of an MTT assay confirming the cytotoxicity of D-alanine and D-Ala-Oi-pr-HCl. Figure 3 shows the results of the luciferase reporter analysis of D-alanine and D-Ala-Oi-pr-HCl and the confirmation of their myostatin expression regulatory effects: (A and B) Results of luciferase assays established using C2C12 cells transfected with a p-myostatin-dependent firefly luciferase reporter plasmid (1 μg) and a β-galactosidase control reporter plasmid (100 ng). Cells were stimulated with each compound (0.001–10 mM) for 24 hours, and luciferase activity was measured using a dual luciferase assay system. Significant differences from the control group were determined using the p-value of a t-test (n=4, *p<0.05, **p<0.01). (C) C2C12 cells were transfected with a p-myostatin-dependent firefly luciferase reporter plasmid (1 μg) and a β-galactosidase control reporter plasmid (100 ng). The cells were then pretreated with D-Ala-Oi-pr-HCl for 3 hours and exposed to 30 ng / ml TNF-α for 24 hours. Data were expressed as mean and SEM (n=3). (D) The gene expression levels of myostatin in C2C12 cells were evaluated using RT-PCR. Cells were pretreated with D-Ala-Oi-pr-HCl for 3 hours and exposed to 30 ng / ml TNF-α for 48 hours. Results were normalized to GAPDH, expressed as a change in folding to 2-CT (mean △△ ± SEM, n=3). Figure 4 shows the results of confirming the expression levels of myostatin and muscle-related molecules following D-Ala-Oi-pr-HCl treatment in C2C12 cells: (A) Western blot analysis results of myostatin in C2C12 myoblasts treated with 30 ng / ml TNF-α and D-Ala-Oi-pr-HCl for 2 days in a dose-dependent manner. (B) The results of treating cells with 0.3 mM D-Ala-Oi-pr-HCl, collecting them at intervals of 12 to 60 hours, and performing Western blot. (C) Results of Western blot analysis of the expression levels of Phospho-Akt, mTOR, and Phospho-ERK after administering D-Ala-Oi-pr-HCl to C2C12 cells in a dose-dependent manner for 30 minutes. (D) The results of treating cells with 0.3 mM D-Ala-Oi-pr-HCl, collecting them at intervals of 12 to 60 hours, and performing Western blot. Figure 5 shows the results of confirming muscle mass and muscle strength in mice with sciatic nerve degeneration sarcopenia following the administration of D-Ala-Oi-pr-HCl: (A) Mean muscle mass of the anterior tibia (TA), quadriceps femoris (Quad), extensor longus (EDL), gastrocnemius (GC), and soleus (SOL) was measured 28 days after D-Ala-Oi-pr-HCl injection. Muscle atrophy induced by sciatic nerve dislocation was assessed using grip strength (B) and the four-limb hanging test (D). Muscle strength (C) was assessed using the grip strength test on day 21 and (E) the four-limb hanging test 28 days after 1 mg / kg D-Ala-Oi-pr-HCl injection. The TA and quadriceps femoris were isolated from each mouse group 28 days after D-Ala-Oi-pr-HCl injection. RT-PCR was performed to assess the gene expression levels of (F) MSTN and (G) MuRF1. Data were normalized to GAPDH and represent the change in folding to 2-△△CT. All values ​​are expressed as mean±SEM (n=7, *p<0.05, **p<0.01). Specific details for implementing the invention

[0030] Hereinafter, embodiments are described in detail with reference to the attached drawings. However, various modifications may be made to the embodiments, and thus the scope of the patent application is not limited or restricted by these embodiments. It should be understood that all modifications, equivalents, and substitutions to the embodiments are included within the scope of the rights.

[0032] The terms used in the embodiments are for illustrative purposes only and should not be interpreted as intended to be limiting. Singular expressions include plural expressions unless the context clearly indicates otherwise. In this specification, terms such as "comprising" or "having" are intended to indicate the existence of the features, numbers, steps, actions, components, parts, or combinations thereof described in the specification, and should be understood as not precluding the existence or addition of one or more other features, numbers, steps, actions, components, parts, or combinations thereof.

[0034] Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as generally understood by those skilled in the art to which the embodiments pertain. Terms such as those defined in commonly used dictionaries should be interpreted as having a meaning consistent with their meaning in the context of the relevant technology, and should not be interpreted in an ideal or overly formal sense unless explicitly defined in this application.

[0036] In addition, when describing with reference to the attached drawings, identical components are assigned the same reference numeral regardless of drawing symbols, and redundant descriptions thereof are omitted. In describing the embodiments, if it is determined that a detailed description of related prior art could unnecessarily obscure the essence of the embodiments, such detailed description is omitted.

[0037] The inventors synthesized a non-natural alanine derivative of the following formula 1 based on a compound of the following formula 2.

[0038] [Chemical Formula 1]

[0039]

[0040] [Chemical Formula 2]

[0041]

[0042] The inventors confirmed that D-alanine isopropyl ester hydrochloride ((R)-isopropyl 2-aminopropanoate hydrochloride, D-Ala-Oi-pr-HCl), a D-alanine derivative having the structure of Formula 1, effectively prevents muscle atrophy in vitro. In addition, in an in vivo study using an animal model of muscle atrophy accompanied by sciatic nerve degeneration, it was confirmed that muscle mass and strength increased, and the gene expression levels of genes related to muscle atrophy were downregulated. These results suggest that D-Ala-Oi-pr-HCl is effective in preventing muscle atrophy and promoting muscle growth.

[0043] Accordingly, the present invention provides D-Ala-Oi-pr-HCl for the improvement, prevention, and treatment of muscle atrophy.

[0044] Muscle atrophy that is subject to improvement, prevention, or treatment in the present invention includes sarcopenia, disuse atrophy, muscle atrophy due to absence of mechanical stimulation, denervational atrophy, cachexia, drug-induced atrophy, malnutritional atrophy, and muscular dystrophy.

[0045] Disuse atrophy of muscles can be a type of muscle atrophy, which can be caused by factors such as casts that prevent the use of muscles.

[0046] The aforementioned disuse atrophy of muscles includes a decrease in muscle thickness caused by activity limitations due to aging or disease, prolonged bed rest, or the use of casts.

[0047] The aforementioned disuse muscle atrophy is associated with various clinical conditions such as peripheral nerve injury, cancer, and sepsis, as well as with prolonged bed rest, cast immobilization of the limbs, and the aging process. Generally, muscle atrophy is accompanied by physiological, histochemical, and biochemical changes resulting from a decrease in muscle protein and can lead to intrinsic dysfunction of skeletal muscle.

[0048] One of the causes of muscle atrophy may be the absence of mechanical stimulation and the denervation of skeletal muscle. In denervated muscle cells, a quantitative decrease in mitochondria and functional abnormalities occur, leading to increased mitochondrial ROS production and consequently an increased rate of muscle cell apoptosis caused by oxidative damage.

[0049] One of the symptoms of cachexia, a severe general weakness seen in the terminal stages of cancer, tuberculosis, hemophilia, etc., is rapid emaciation.

[0050] Muscular dystrophy is characterized by muscle atrophy and weakness caused by the absence of the formation of the dystrophin-glycoprotein complex, a component of the striated muscle plasma membrane, due to a gene mutation.

[0051] Cortisol is a substance that can be secreted in the body due to various acute stressors; while it plays a role in supplying energy to counteract stress, it can also cause muscle atrophy depending on its mechanism.

[0052] Synthetic corticosteroids can cause adverse reactions such as steroidal myopathy and damage to muscle parenchyma.

[0053] As used herein, the term "prevention" refers to any act of suppressing or delaying the onset of muscle atrophy through the administration of a composition. In the present invention, the term "treatment" refers to any act of improving or beneficially altering the symptoms of muscle atrophy through the administration of a composition.

[0054] Since the above pharmaceutical composition can reduce myostatin promoter activity, it can more fundamentally prevent and treat muscle loss and muscle strength reduction.

[0055] A pharmaceutical composition for the prevention or treatment of muscle atrophy according to one embodiment of the present invention may contain the non-natural amino acid derivative at a concentration of 0.001 mM or higher, and specifically may contain it at a concentration of 0.001 mM to 10 mM.

[0056] The pharmaceutical composition of the present invention may be prepared by methods known in the pharmaceutical field for use as a drug, and may be prepared and used in formulations such as powder, granules, tablets, capsules, or injections by mixing with pharmaceutically acceptable carriers, excipients, diluents, stabilizers, preservatives, etc. In addition, the composition may be prepared as a sustained-release formulation by including a base used for sustained-release purposes in addition to the active ingredient, so that the release of the active ingredient occurs slowly.

[0057] Pharmaceutically acceptable carriers may additionally include, for example, carriers for oral administration or carriers for parenteral administration. Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, etc. Additionally, they may include various drug delivery materials used for oral administration of peptide preparations. Furthermore, carriers for parenteral administration may include water, suitable oils, saline solution, aqueous glucose and glycol, etc., and may additionally include stabilizers and preservatives. Suitable stabilizers include antioxidants such as sodium bisulfite, sodium sulfite, or ascorbic acid. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol. In addition to the above components, the pharmaceutical composition of the present invention may additionally include lubricants, humectants, sweeteners, flavorings, emulsifiers, suspending agents, etc.

[0058] Examples of the above diluents include non-aqueous solvents such as propylene glycol, polyethylene glycol, vegetable oils such as olive oil and peanut oil, or aqueous solvents such as brine (preferably 0.8% brine) and water containing a buffer medium (preferably 0.05M phosphate buffer), but are not limited thereto.

[0059] Examples of the above excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, wheat flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, anhydrous skim milk, glycerol, propylene, glycol, water, ethanol, etc., but are not limited thereto.

[0060] Examples of the above stabilizers include carbohydrates such as sorbitol, mannitol, starch, sucrose, dextran, glutamate, and glucose, or proteins such as milk powder, serum albumin, and casein, which are animal, plant, or microbial proteins, but are not limited thereto.

[0061] Examples of the above preservatives include thimerosal, merthioleate, gentamicin, neomycin, nystatin, amphotericin B, tetracycline, penicillin, streptomycin, polymyxin B, etc., but are not limited thereto.

[0062] The pharmaceutical composition of the present invention may be administered to mammals, including humans, by any method, for example, orally or parenterally. Parenteral administration methods may include, but are not limited to, intravenous, intramuscular, intra-arterial, intramedullary, intradural, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual, or rectal administration.

[0063] The pharmaceutical composition of the present invention can be formulated as an oral or parenteral administration preparation according to the administration route described above.

[0064] The total effective amount of the pharmaceutical composition of the present invention may be administered to a patient as a single dose, or administered via a divided therapy regimen involving multiple doses over a long period. The content of the active ingredient in the pharmaceutical composition of the present invention may vary depending on the severity of the disease. This can be determined by considering various factors, such as the formulation method, route of administration, and frequency of treatment, as well as the patient's age, weight, health status, symptoms of the disease, and the time and method of administration. Considering these points, a person skilled in the art will be able to determine an appropriate effective dose of the composition of the present invention. The pharmaceutical composition according to the present invention is not particularly limited in terms of formulation, route of administration, and method of administration, as long as it exhibits the effects of the present invention.

[0065] The composition of the present invention may be added to food intended for the prevention or improvement of muscle atrophy, and said food may be a health functional food. In the present invention, a health functional food refers to a food having bio-regulatory functions such as the prevention or improvement of disease, biological defense, immunity, or recovery after illness, and must be harmless to the human body when consumed over a long period.

[0066] When the composition of the present invention is used as a food additive, the non-natural alanine derivative may be added as is or used together with other foods or food ingredients, and may be used appropriately according to conventional methods. The amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health, or therapeutic treatment). Generally, when manufacturing food or beverages, the composition of the present invention is added in an amount of 15% by weight or less, preferably 10% by weight or less, relative to the raw material. However, in the case of long-term consumption for the purpose of health and hygiene or health control, the amount may be below the above range, and since there are no issues regarding safety, the active ingredient may be used in an amount greater than the above range.

[0067] There are no special restrictions on the types of the above-mentioned foods. Examples of foods to which the above-mentioned substance may be added include meat, sausage, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, and include all health foods in the conventional sense.

[0068] The health beverage composition of the present invention may include various flavoring agents or natural carbohydrates, etc., as additional ingredients, similar to conventional beverages. The aforementioned natural carbohydrates may include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and natural sweeteners such as dextrin and cyclodextrin, or synthetic sweeteners such as saccharin and aspartame. The proportion of the natural carbohydrates is generally about 0.01 to 10 g, preferably about 0.01 to 0.1 g, per 100 ml of the composition of the present invention.

[0069] In addition to the above, the composition of the present invention may include various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. Furthermore, the composition of the present invention may include fruit pulp for the production of natural fruit juices, fruit juice beverages, and vegetable beverages. These ingredients may be used independently or in combination. Although the proportion of these additives is not critical, it is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

[0070] The present invention will be explained in more detail below through examples. The following examples are described for the purpose of illustrating the present invention and do not limit the scope of the present invention.

[0071] [Synthesis and Analysis of D-Alanine Derivatives]

[0072] 1. Synthesis of D-Alanine Derivatives

[0073] After adding dodecanol 2 (3.86 mL, 50.5 mmol) to a lot of a solution of D-amino acid (5 g, 56.1 mmol) stirred in toluene (100 mL), pTSA (Toluene-4-sulfonic acid monohydrate, 11.75 g, 61.7 mmol) was added. After addition, the temperature of the reaction mixture was gradually raised to the reflux temperature, water was separated, and the reaction mixture was monitored by TLC. The reaction mixture was concentrated under vacuum, the resulting residue was taken in ethyl acetate (200 mL), washed with 5% Na2CO3 (3 x 50 mL) aqueous solution, and the brine solution was taken. The organic layer was dried over NaS and concentrated under vacuum to liquefy the crude dodecyl compound. A stirred solution of ethyl acetate / hexane / MeOH (10:10:1 mL) containing the compound (5 g, 17.54 mmol) was cooled to 0°C. The reaction mixture was stirred with 1N HCl at 50°C for 60 minutes, and the reaction mixture was monitored by TLC. The reaction mixture was concentrated under vacuum, and the resulting residue was subsequently oxidized with ethyl acetate (3 x 52 mL) followed by hexane (5 x 50 mL) to make the wet compound (9.1 g) semi-solid. The semi-solid was taken in ethyl acetate / hexane (10:10 mL), heated under reflux, and stirred under reflux for 30 minutes. The reaction mixture was slowly cooled to RT and then cooled to 0°C. The resulting solid was filtered under nitrogen and dried under vacuum to obtain an ester salt as a white hygroscopic solid.

[0075] 2. Characterization of D-Alanine Derivatives

[0076] D-Alanine Isopropyl Ester Hydrochloride (D-Ala-Oi-pr-HCl) (Yield: 93%)

[0077]

[0078] 1H NMR(DO), δ (ppm): 4.04~4.09[m, 1H, (-CHCOO-CH-)], 1.54~56[m, 9H, (-CH2-CH3)], 1.25 [brs, 1H, (CH, alkyl chain)]; 13C NMR (DMSO-d6), δ (ppm): 173.28, 85.40, 49.34, 27.00, 15.40; LRMS (FAB+) for C6H14ClNO2 [M+H]+ Calcd: 168, Found: 168

[0080] [Experimental Method]

[0081] 1. Density Functional Theory Calculation

[0082] Density functional theory (DFT) calculations were performed to verify the physical and chemical properties of D-alanine and D-Ala-Oi-pr-HCl using Gaussian 16 and Gauss-View 6.0 programs. The optimized shape was analyzed using the DFT method at the Becke three-parameter Lee-Yang-Parr (B3LYP) level. Subsequently, single-point calculations for the optimized shape were performed using the 6-311G++(d, p) basic set under water solvent conditions. After the molecular shape was fully optimized, thermodynamic functions and parameters (Gibbs free energy G) were obtained through vibration frequency calculations. Temperature-dependent enthalpy correction and entropy were calculated at 298 K and 1 atm pressure.

[0084] 2. Cell Culture

[0085] C2C12 myoblasts were cultured in Dulbecco's modified Eagle's medium containing 10% FBS (Gibco BRL, Carlsbad, CA), 100 U / mL penicillin, and 100 μg / mL streptomycin. Cells were maintained at 37°C in an incubator under a 5% CO2 and humidified environment.

[0087] 3. Cell viability analysis

[0088] Cell proliferation was measured using the MTT assay. C2C12 cells were 1 × 10⁶ in a 96-well plate. 3 Cells were seeded at a cell / well density. Cells were treated with each compound at different concentrations (0.001–10 mM) and maintained for 24, 48, and 72 hours. Absorbance was measured at 540 nm using a microplate reader (BioTek, Santa Clara, CA) 2 hours after the addition of 0.5 mg / ml MTT (final concentration). Data were normalized to the percentage of the control group.

[0090] 4. Construction of Luciferase Reporter Plasmid and Performance of Luciferase Reporter Analysis

[0091] A luciferase reporter was used to evaluate the activity of the MSTN promoter (1kb) using the pGL4.15 vector. The PCR product was cloned into the pGL4.15 vector at the NheI site, and the resulting clones were verified by DNA sequencing. C2C12 cells were transiently co-transfected with the myostatin promoter construct and the β-galactosidase reporter plasmid using Lipofectamine 2000 (Invitrogen). Subsequently, the culture medium was replaced with complete medium. After 24 hours of treatment, the luciferase activity of the cell lysates was analyzed using a luciferase assay reagent (Promega), and luminescence was measured using an EnSpire multimode reader (PerkinElmer). The primers used for PCR are shown in Table 1 below.

[0092] SEQ NO. Primer Sequence (5' 3') 1 Forward CGG TAC CTG AGC TCG CTA GCC CTG GAA GCC TGA GTC AAA C 2 Reverse CTT GAT ATC CTC GAG GCT AGC CAG CAA TCA GCA CAA ACA GG

[0093] 5. Real-time PCR

[0094] Total RNA was isolated using QIAzol lysis reagent (Qiagen). RNA concentration was measured using a NanoDrop spectrophotometer (Thermo Fisher Scientific). 2 μg of total RNA from each sample was reverse transcribed into cDNA using AMV reverse transcriptase (Promega) and oligo dT primers according to the manufacturer's instructions. mRNA expression was evaluated by Real-Time PCR (QuantStudio 3 Real-Time PCR, Thermo Fisher Scientific) using the SYBR Green system (TOPreal™ qPCR 2X PreMIX, Enzynomics). Relative expression levels were normalized to GAPDH mRNA levels in each sample. Fold change values ​​were calculated using the ΔΔCt method. The primers used are listed in Table 2 below.

[0095] SEQ NO. Gene Primer Sequence (5' 3') 3 Myostatin Forward GCA CTG GTA TTT GGC AGA GT 4 Reverse TTC AGC CCA TCT TCT CCT GG 5 MuRF1 Forward CCA AGG AGA ATA GCC ACC AG 6 Reverse AGG ATC AGA GCC TCG ATG AA 7 GAPDH Forward GTG TTC CTA CCC CCA ATG TG 8 Reverse CCT GCT TCA CCA CCT TCT TG

[0096] 6. Western Blot

[0097] C2C12 cells were lysed in ice-cold lysis buffer (50 mM Tris-HCl [pH 7.4], 1% Triton X-100, 0.25% sodium deoxycholate, 150 mM EDTA, 1 mM sodium orthovanadate, 1 mM NaF, and 1 mM phenylmethylsulfonyl fluoride). Proteins were separated on a 10% SDS-PAGE gel and transferred to a 0.45 μm nitrocellulose membrane (GE Healthcare). The membrane was blocked in 5% dry milk (w / v) for 1 hour and washed three times with Tris-buffered saline containing Triton X-100. The membranes were then incubated overnight at 4°C with primary antibodies against anti-mTOR (Cell Signaling; #2972), anti-p-Akt (S473) (Cell Signaling; #4060), anti-p-Erk (Cell Signaling; #9101), anti-p-FoxO3a (Ser253) (Cell Signaling; #9466), and anti-p-Smad3 (Cell Signaling; #9520), followed by irradiation with secondary antibodies conjugated to HRP for 1 hour (Enzo Life Sciences). The blots were visualized using the Amersham Biosciences ECL detection system (GE Healthcare).

[0099] 7. Animal Care

[0100] Experimental animals were housed in the facility in accordance with the Animal Care and Use Committee of the Korea University Institutional Safety Code. All animals used in the experiment were 10-week-old male C57BL / 6 mice (Central Lab. Animal Inc.), fed a normal diet and water, housed in cages with automatically controlled lighting (12 hours on, 12 hours off), and maintained at a stable temperature of 23°C.

[0102] 8. Animal Experiment Design and Denervation Sarcopenia Model

[0103] 12-week-old male WT mice were randomly divided into four groups (n=10) and anesthetized by inhaling a mixture of isoflurane (3%) (Isotry, Troikaa) and oxygen (97%). Surgery was performed in all three experimental groups via surgical resection of the sciatic nerve in the left hind leg. The wounds were sutured with surgical sutures. After surgery, the mice were administered as follows: in group (a) (sham), 1X PBS was injected intraperitoneally; in group (b) (control), 1X PBS was injected intraperitoneally; in group (c), D-Ala-Oi-pr-HCl (1 mg / kg) was injected intraperitoneally; injections were administered every two days for 28 days based on mouse body weight. On day 28, the mice were sacrificed, blood was collected, and skeletal muscles were dissected. The data shown are the average of all experimental sets.

[0105] 9. Grip strength test

[0106] Grip strength was evaluated using a dynamometer with a horizontal mesh (San BIOSEB, BIO-GS3). Each rat was positioned 2 cm from the base of its tail and allowed to grasp the metal mesh attached to the device with its paw, after which it was gently pulled until it released its hand. Measurements were repeated three times for each mouse. The maximum force values ​​of each measurement were averaged and normalized to body weight.

[0108] 10. Four-limb hanging test

[0109] The rat was placed on a grid and then inverted over a cage filled with bedding. The experiment was terminated when a hanging time of 600 seconds was achieved or when the rat fell off earlier after three sessions. The maximum hanging time was used for interpretation.

[0111] 11. Statistical Analysis

[0112] Statistical analysis was performed using GraphPad Prism 7 (GraphPad). Data are expressed as mean ± SEM. Statistically significant differences were determined using the p-values ​​of a two-sample t-test (*p<0.05, **p<0.01).

[0114] [Experimental Results]

[0115] 1. Density Functional Theory Calculation

[0116] Table 3 below shows the optimized molecular structures of D-alanine and its derivatives in water.

[0117] Property D -alanine D -Ala-O i -pr-HCl EE + Thermal Free Energy Correction -323.7896 -902.5463 EE + Thermal Enthalpy Correction -323.7508 -902.4896 EE + Thermal Energy Correction -323.7517 -902.4906 EE + Zero-point Energy -323.7587 -902.5039 E (Thermal) kcal / mol 71.6790 137.3920 Entropy (S) cal / mol-kelvin 81.7540 119.3350 Polarizability (α) au 67.0603 135.4676 Dipole Moment, Debye 1.8173 14.8131 EHOMO (eV) -0.2658 -0.2646 ELUMO (eV) -0.0175 -0.0302 Energy gap (eV) HOMO-LUMO gap (ΔHL) 0.2483 0.2344 Ionisation potential,I = - EHOMO(eV) 0.2659 0.2647 Electron affinity,A = - ELUMO(eV) 0.0176 0.0303 Electronegativity, χ(eV)(χ = I + A / 2) 0.1417 0.1475 Global hardness, η = I - A / 2 (eV) 0.1242 0.1172 Chemical potential, μ = -(I + A) / 2(eV) -0.1417 -0.1475 Global electrophilicity, ω = μ2 / 2η(eV) 0.0809 0.0928 Chemical softness, S = 1 / η(eV) 8.0541 8.5324

[0118] In drug optimization, an enhanced dipole moment can improve hydrogen bonding and non-bonding interactions of drug-receptor complexes, which are essential for increasing binding affinity. Furthermore, the energies of HOMO and LUMO play a significant role in chemical reactivity, and the HOMO and LUMO band gaps are related to the physicochemical indices of the molecule. The HOMO-LUMO energy gap, hardness, chemical potential, electrophilicity, and softness were calculated for D-alanine and D-Ala-Oi-pr-HCl (Fig. 1). As shown in the results in Table 3, D-Ala-Oi-pr-HCl has the lowest energy gap (0.2344 eV), and the softness (hardness) value is 8.5324 eV (0.1172 eV). These parameters provide information regarding molecular stability and electron transfer and can contribute to higher chemical reactivity. The global electrophilicity exponent (ω) determines energy stabilization when a molecular system acquires additional charge from its surroundings. The negative chemical potential value (-0.1475 eV) of D-Ala-Oi-pr-HCl indicates stability. The intended target site can be determined by the softness, hardness, and electronegativity of the drug and the target site. Furthermore, compounds with the lowest energy gap and softness may exhibit higher chemical activity and polarization than other compounds. Adding electrons to higher LUMOs or removing electrons from lower HOMOs is energetically favorable for all potential reactions (Table 3). Neither compound exhibited significant cytotoxic activity up to 10 mM (Fig. 2).

[0120] 2. Effects of D-Alanine and D-Ala-Oi-pr-HCl on Muscle Atrophy

[0121] To confirm the effects of alanine on muscle atrophy, C2C12 myoblasts were treated with D-alanine and D-Ala-Oi-pr-HCl. D-alanine significantly reduced the promoter activity of myostatin at 1 mM and 10 mM (Fig. 3A). D-Ala-Oi-pr-HCl significantly downregulated the promoter activity of myostatin at 0.1, 1, and 10 mM (Fig. 3B). Myostatin promoter activity induced by 30 ng / ml TNF-α was nearly twofold. At 3 mM of D-Ala-Oi-pr-HCl, it was significantly reduced by 10% (Fig. 3C). TNF-α increased the mRNA expression levels of myostatin by more than threefold. D-Ala-Oi-pr-HCl significantly reduced myostatin expression in a dose-dependent manner (Fig. 3D).

[0123] 3. Effects of D-Ala-Oi-pr-HCl on Cell Signaling Pathways

[0124] Western blot analysis confirmed that the induction of myostatin expression by TNF-α was dose-dependently inhibited by D-Ala-Oi-pr-HCl in C2C12 myoblasts (Fig. 4A). The protein expression level of myostatin was reduced in a time-dependent manner by D-Ala-Oi-pr-HCl at a concentration of 0.3 mM (Fig. 4B).

[0125] To investigate the dose- and time-dependent effects of myostatin on cell signaling pathways, C2C12 myoblasts were treated with D-Ala-Oi-pr-HCl. The effects of D-Ala-Oi-pr-HCl on cell signaling pathways were investigated using various antibodies. The expression levels of mTOR and phospho-Akt increased in a dose-dependent manner with D-Ala-Oi-pr-HCl treatment. Additionally, phospho-ERK signaling increased as the concentration of D-Ala-Oi-pr-HCl increased up to 1 mM, but decreased at a concentration of 3 mM. mTOR expression was upregulated after treatment with D-Ala-Oi-pr-HCl. Both Akt and ERK were phosphorylated by D-Ala-Oi-pr-HCl (Fig. 4C). The expression levels of mTOR and phospho-Akt increased up to 30 minutes. In addition, the phospho-ERK signal decreased until 30 minutes and increased after 30 minutes (Fig. 4D).

[0127] 4. Effects of D-ala-Oi-pr-HCl in a deneuropathy mouse model

[0128] To evaluate the efficacy of D-Ala-Oi-pr-HCl in animals, a sciatic nerve degeneration sarcopenia model was constructed. The drug was administered every two days for four weeks. This data demonstrated that sciatic nerve injury causes muscle atrophy. In the control group, the weight of leg muscles, including the tibialis anterior (TA), quadriceps (Quad), extensor digitorum longus (EDL), gastrocnemius (GC), and soleus (SOL), was significantly reduced compared to the sham group (control group). Additionally, the weight of all muscles increased significantly in the group treated with D-Ala-Oi-pr-HCl (Fig. 5A).

[0129] To evaluate muscle strength, grip strength and a four-legged hanging test were performed. The results of the grip strength and four-legged hanging test showed that the detachable control group was significantly reduced compared to the sham (control group) (Figs. 5B, D). In the group treated with D-Ala-Oi-pr-HCl, grip strength significantly increased compared to the control group (Fig. 5C). In the group treated with D-Ala-Oi-pr-HCl, the hanging time significantly increased compared to the control group (Fig. 5E).

[0130] The expression of genes related to muscle atrophy was confirmed in TA and Quad tissues using RT-PCR. In both TA and Quad tissues, the gene expression levels of myostatin (MSTN) demonstrated that denervation induces muscle atrophy. A significant decrease in myostatin expression, similar to that observed in the sham group, was observed in the 1 mg / kg group. In the quadriceps femoris, the 1 mg / kg D-Ala-Oi-pr-HCl group showed a significant decrease in myostatin expression levels (Fig. 5F). The gene expression levels of MuRF1 also confirmed that denervation induces muscle atrophy in both TA and Quad tissues. MuRF1 gene expression levels were significantly reduced in the 1 mg / kg D-Ala-Oi-pr-HCl treated group in TA muscle. Furthermore, in quadriceps femoris tissue, MuRF1 expression levels showed a trend similar to that of MSTN (Fig. 5F, G).

[0131] Serum biochemical tests were performed to analyze blood samples from each group (Table 4).

[0132]

[0133] As a result, levels of albumin (ALB), blood urea nitrogen (BUN), cholesterol, low-density lipoprotein (LDL), free fatty acids (FFA), lactate dehydrogenase (LDH), inorganic phosphate, and lactate were found to be significantly higher in the control group than in the Sham group. In the group treated with D-Ala-Oi-pr-HCl, levels of albumin, cholesterol, LDL, and FFA were significantly lower in the D-Ala-Oi-pr-HCl treatment group compared to the control group, showing results similar to the Sham group. Lactate levels were significantly reduced in the D-Ala-Oi-pr-HCl treatment group, but not as low as in the Sham group. BUN and LDH levels decreased after D-Ala-Oi-pr-HCl treatment, but this decrease was not significant in the 1 mg / kg D-Ala-Oi-pr-HCl group. No significant differences were observed between groups regarding other parameters.

[0135] Although the embodiments have been described above with reference to the limited drawings, those skilled in the art can apply various technical modifications and variations based on the above. For example, suitable results may be achieved even if the described techniques are performed in a different order than described, and / or if the components of the described system, structure, device, circuit, etc. are combined or assembled in a form different from described, or replaced or substituted by other components or equivalents.

[0136] Therefore, other implementations, other embodiments, and equivalents to the claims also fall within the scope of the claims set forth below.

Claims

Claim 1 delete Claim 2 A pharmaceutical composition for the prevention or treatment of muscle atrophy comprising a non-natural alanine derivative as an active ingredient, wherein the non-natural alanine derivative is a D-alanine isopropyl ester hydrochloride having the structure of Chemical Formula 1 below. [Chemical Formula 1] Claim 3 In paragraph 2, the above composition is a pharmaceutical composition for the prevention or treatment of muscle atrophy, wherein the composition reduces myostatin promoter activity. Claim 4 A pharmaceutical composition for the prevention or treatment of muscle atrophy according to claim 2, characterized in that the composition comprises the non-natural alanine derivative at a concentration of 0.001 mM to 10 mM. Claim 5 A pharmaceutical composition according to claim 2, wherein the muscle atrophy is one or more muscle atrophies selected from the group consisting of sarcopenia, disuse atrophy, muscle atrophy due to absence of mechanical stimulation, denervational atrophy, cachexia, drug-induced atrophy, malnutritional atrophy, and muscular dystrophy. Claim 6 A preparation for the prevention or treatment of muscle atrophy, characterized by comprising one or more selected from the group consisting of pharmaceutically acceptable carriers, excipients, diluents, stabilizers, and preservatives, and the pharmaceutical composition described in claim 2. Claim 7 A preparation for the prevention or treatment of muscle atrophy, characterized in that, in claim 6, the pharmaceutically acceptable carrier comprises a carrier for oral administration or a carrier for parenteral administration. Claim 8 A food composition for preventing or improving muscle atrophy comprising a non-natural alanine derivative as an active ingredient, wherein the non-natural alanine derivative is a D-alanine isopropyl ester hydrochloride having the structure of Chemical Formula 1 below. [Chemical Formula 1]

Citation Information

Patent Citations

  • Novel preparation method of L-alanine isopropyl ester hydrochloride

    CN106518694A

  • Synthesis method of intermediate L-alanine isopropyl ester hydrochloride

    CN109467515A